We are live on ! Find out more
NIG

NFJ Investment Group Portfolio holdings

AUM $2.64B
1-Year Est. Return 23.86%
This Fund
S&P 500
This Quarter Est. Return
-3.42%
1 Year Est. Return
+23.86%
3 Year Est. Return
+46.54%
5 Year Est. Return
+49.74%
10 Year Est. Return
AUM
$3.11B
AUM Growth
-$303M
Cap. Flow
-$135M
Cap. Flow %
-4.35%
Top 10 Hldgs %
21.71%
Holding
283
New
12
Increased
29
Reduced
224
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.5M
4
PFE icon
Pfizer
PFE
+$11M
5
AMD icon
Advanced Micro Devices
AMD
+$7.66M

Top Sells

Rank Stock Value
1
UGI icon
UGI
UGI
+$24.6M
2
IDXX icon
Idexx Laboratories
IDXX
+$12.7M
3
WKC icon
World Kinect Corp
WKC
+$11.2M
4
EL icon
Estee Lauder
EL
+$10.2M
5
TGT icon
Target
TGT
+$9.2M

Sector Composition

Rank Sector Weight
1 Financials 24.63%
2 Real Estate 14.08%
3 Healthcare 11.73%
4 Technology 9.5%
5 Industrials 8.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BCS icon
251
Barclays
BCS
$94.1B
$453K 0.01%
34,087
-3,753
-10% -$48.6K
AZN icon
252
AstraZeneca
AZN
$250B
$445K 0.01%
3,394
-302
-8% -$42.3K
PBR icon
253
Petrobras
PBR
$116B
$428K 0.01%
33,276
+6,508
+24% +$90.9K
YMM icon
254
Full Truck Alliance
YMM
$9.99B
$423K 0.01%
39,096
-5,292
-12% -$51.6K
SONY icon
255
Sony
SONY
$138B
$419K 0.01%
19,820
-38,400
-66% -$748K
WPM icon
256
Wheaton Precious Metals
WPM
$60.9B
$378K 0.01%
6,723
-519
-7% -$32.1K
BN icon
257
Brookfield
BN
$108B
$363K 0.01%
9,465
-3,494
-27% -$132K
BBVA icon
258
Banco Bilbao Vizcaya Argentaria
BBVA
$156B
$322K 0.01%
33,120
-5,984
-15% -$59.2K
MELI icon
259
Mercado Libre
MELI
$92.3B
$248K 0.01%
146
-98
-40% -$191K
EGP icon
260
EastGroup Properties
EGP
$10.9B
$228K 0.01%
1,423
-22
-2% -$3.8K
GMAB icon
261
Genmab
GMAB
$19.5B
$213K 0.01%
10,185
-2,059
-17% -$45.2K
EW icon
262
Edwards Lifesciences
EW
$51.7B
$28.3K ﹤0.01%
382
-22,816
-98% -$1.6M
NOW icon
263
ServiceNow
NOW
$129B
$25.4K ﹤0.01%
120
PLNT icon
264
Planet Fitness
PLNT
$3.78B
$20K ﹤0.01%
202
IDXX icon
265
Idexx Laboratories
IDXX
$46.2B
$12.4K ﹤0.01%
30
-29,031
-100% -$12.7M
CRL icon
266
Charles River Laboratories
CRL
$12.8B
$10.3K ﹤0.01%
56
ACM icon
267
Aecom
ACM
$9.75B
$1.5K ﹤0.01%
14
-2,673
-99% -$292K
BEKE icon
268
KE Holdings
BEKE
$18.8B
$1.42K ﹤0.01%
77
CWEN icon
269
Clearway Energy Class C
CWEN
$6.7B
$1.27K ﹤0.01%
49
-120,032
-100% -$3.32M
SOBO
270
South Bow Corp
SOBO
$7.43B
$162 ﹤0.01%
+7
New +$171
DOV icon
271
Dover
DOV
$28.4B
-4
Closed -$767
EL icon
272
Estee Lauder
EL
$32B
-102,310
Closed -$10.2M
F icon
273
Ford
F
$55.7B
-837,248
Closed -$8.84M
LDOS icon
274
Leidos
LDOS
$17.3B
-19,702
Closed -$3.21M
MGPI icon
275
MGP Ingredients
MGPI
$375M
-38,206
Closed -$3.18M

Similar funds

NFJ Investment Group's Q4 2024 Portfolio in Review

As of Q4 2024, NFJ Investment Group held 283 positions worth $3.11B, down 8.9% from $3.42B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

NFJ Investment Group withdrew a net $135M in Q4 2024, closing 13 positions and reducing 224 holdings. Its most notable exit was UGI, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Financials at 25% of assets, up from 23% a quarter earlier, followed by Real Estate and Healthcare.

Against the trend, NFJ Investment Group opened a new position in Bristol-Myers Squibb worth $12.6M.

  • NFJ Investment Group's largest Q4 2024 buy was Bristol-Myers Squibb: 222,089 shares worth $12.6M.
  • NFJ Investment Group added most to Pfizer in Q4 2024, an estimated $11M increase.
  • NFJ Investment Group's biggest Q4 2024 reduction was Idexx Laboratories, cutting an estimated $12.7M.
  • NFJ Investment Group fully exited UGI in Q4 2024, selling an estimated $24.6M.
  • NFJ Investment Group's ten largest holdings make up 22% of its $3.11B portfolio in Q4 2024.
  • NFJ Investment Group opened 12 new positions and closed 13 in Q4 2024.
  • NFJ Investment Group's portfolio value fell 8.9% quarter-over-quarter to $3.11B.

Based on NFJ Investment Group's 13F filing for Q4 2024, filed 13 Feb 2025.